Sun Pharmaceutical Industries Ltd.
17/B, Mahal Industrial Estate,
Mahakali Caves Road,
Andheri (East), Mumbai 400 093 India
Tel.: (91-22) 6645 5645 Fax.: (91-22) 6645 5685
CIN: L24230GJ1993PLC019050
www.sunpharma.com

FOR IMMEDIATE RELEASE

Sun Pharma announces settlement of litigation for generic Gleevec® in US

Mumbai, May 15, 2014: Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) today announced that one of its subsidiaries has executed a settlement agreement with Novartis Pharmaceuticals Corporation stipulating a dismissal of the lawsuits filed in the United States against the Company regarding submission of an Abbreviated New Drug Application (ANDA) for a generic version of Gleevec®, Imatinib Mesylate tablets. These tablets are indicated for the treatment of chronic myeloid leukemia.

Under the terms of the settlement agreement, Sun Pharma's subsidiary may launch its version of generic Gleevec® in the United States on February 1, 2016. The other terms of the agreement are confidential. The agreement is subject to customary regulatory approvals.

Sun Pharma's subsidiary holds a tentative approval from the US FDA for its ANDA for a generic version of Gleevec®. As per IMS, Gleevec® had annual sales of approximately US$ 2 billion in the US.

Gleevec® is the registered trademark of Novartis Pharmaceuticals Corporation.

About Sun Pharma

Established in 1983, listed since 1994 and headquartered in India, Sun Pharmaceutical Industries Ltd. (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) is an international specialty pharmaceutical company with over 72% sales from global markets. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in US, India and several other markets across the world. For the year ending March 2013, overall revenues were at US$2.1 billion, of which US contributed US$1.1 billion. In India, the company is a leader in niche therapy areas of psychiatry, neurology, cardiology, nephrology, gastroenterology, diabetology, orthopedics and ophthalmology. The company has strong skills in product development, process chemistry, and manufacturing of complex dosage forms. More information about the company can be found at www.sunpharma.com.

Contacts

Nimish Desai
Tel +91 22 6645 5645, Xtn 5717
Tel Direct +91 22 6645 5717
Mobile +91-98203 30182
E mail nimish.desai@sunpharma.com

Frederick Castro
Tel +91 22 6645 5645, Xtn 5964
Tel Direct +91 22 6645 5964
Mobile +91 99206 65176
E mail frederick.castro@sunpharma.com